Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Troels H. Borch"'
Publikováno v:
Clinical Cancer Research. :OF1-OF9
After a positive phase III trial, it is evident that treatment with tumor-infiltrating lymphocytes (TIL) is a safe, feasible, and effective treatment modality for patients with metastatic melanoma. Further, the treatment is safe and feasible in diver
Autor:
Maartje W. Rohaan, Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, Bastiaan Nuijen, Cynthia Nijenhuis, Inge Jedema, Maaike van Zon, Saskia Scheij, Jos H. Beijnen, Marten Hansen, Carlijn Voermans, Inge M. Noringriis, Tine J. Monberg, Rikke B. Holmstroem, Lidwina D.V. Wever, Marloes van Dijk, Lindsay G. Grijpink-Ongering, Ludy H.M. Valkenet, Alejandro Torres Acosta, Matthias Karger, Jessica S.W. Borgers, Renske M.T. ten Ham, Valesca P. Retèl, Wim H. van Harten, Ferry Lalezari, Harm van Tinteren, Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A.M. Stevense-den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan-Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers-Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebaek, Lisbet R. Hölmich, Alexander C.J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, Aafke Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen
Publikováno v:
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOC
The New England Journal of Medicine, 387, 2113-2125
New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
Rohaan, M W, Borch, T H, Van Den Berg, J H, Met, Ö, Kessels, R, Geukes Foppen, M H, Stoltenborg Granhøj, J, Nuijen, B, Nijenhuis, C, Jedema, I, Van Zon, M, Scheij, S, Beijnen, J H, Hansen, M, Voermans, C, Noringriis, I M, Monberg, T J, Holmstroem, R B, Wever, L D V, Van Dijk, M, Grijpink-Ongering, L G, Valkenet, L H M, Torres Acosta, A, Karger, M, Borgers, J S W, Ten Ham, R M T, Retèl, V P, Van Harten, W H, Lalezari, F, Van Tinteren, H, Van Der Veldt, A A M, Hospers, G A P, Stevense-Den Boer, M A M, Suijkerbuijk, K P M, Aarts, M J B, Piersma, D, Van Den Eertwegh, A J M, De Groot, J W B, Vreugdenhil, G, Kapiteijn, E, Boers-Sonderen, M J, Fiets, W E, Van Den Berkmortel, F W P J, Ellebaek, E, Hölmich, L R, Van Akkooi, A C J, Van Houdt, W J, Wouters, M W J M, Van Thienen, J V, Blank, C U, Meerveld-Eggink, A, Klobuch, S, Wilgenhof, S, Schumacher, T N, Donia, M, Svane, I M & Haanen, J B A G 2022, ' Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. ', New England Journal of Medicine, vol. 387, no. 23, pp. 2113-2125 . https://doi.org/10.1056/NEJMoa2210233
The New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOCIETY
The New England Journal of Medicine, 387, 23, pp. 2113-2125
The New England Journal of Medicine, 387, 2113-2125
New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
Rohaan, M W, Borch, T H, Van Den Berg, J H, Met, Ö, Kessels, R, Geukes Foppen, M H, Stoltenborg Granhøj, J, Nuijen, B, Nijenhuis, C, Jedema, I, Van Zon, M, Scheij, S, Beijnen, J H, Hansen, M, Voermans, C, Noringriis, I M, Monberg, T J, Holmstroem, R B, Wever, L D V, Van Dijk, M, Grijpink-Ongering, L G, Valkenet, L H M, Torres Acosta, A, Karger, M, Borgers, J S W, Ten Ham, R M T, Retèl, V P, Van Harten, W H, Lalezari, F, Van Tinteren, H, Van Der Veldt, A A M, Hospers, G A P, Stevense-Den Boer, M A M, Suijkerbuijk, K P M, Aarts, M J B, Piersma, D, Van Den Eertwegh, A J M, De Groot, J W B, Vreugdenhil, G, Kapiteijn, E, Boers-Sonderen, M J, Fiets, W E, Van Den Berkmortel, F W P J, Ellebaek, E, Hölmich, L R, Van Akkooi, A C J, Van Houdt, W J, Wouters, M W J M, Van Thienen, J V, Blank, C U, Meerveld-Eggink, A, Klobuch, S, Wilgenhof, S, Schumacher, T N, Donia, M, Svane, I M & Haanen, J B A G 2022, ' Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. ', New England Journal of Medicine, vol. 387, no. 23, pp. 2113-2125 . https://doi.org/10.1056/NEJMoa2210233
The New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOCIETY
The New England Journal of Medicine, 387, 23, pp. 2113-2125
Item does not contain fulltext BACKGROUND: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 tr
Table S1 shows recruiting TIL trials for patients with non-melanoma solid cancers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cca0805fa76ac4545b67e10ef8bdeaa
https://doi.org/10.1158/1078-0432.22734073
https://doi.org/10.1158/1078-0432.22734073